Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 286B is a transcription factor containing zinc finger domains, which confer DNA-binding capability and allow it to regulate gene expression in human cells[1][7]. It is suggested to act primarily by controlling transcription through interactions with specific DNA sequences. ZNF286B arose recently through gene duplication from ZNF286A, leading to structural differences—most notably, loss of the KRAB domain found in ZNF286A. This KRAB-less isoform is hypothesized to permit novel regulatory functions, including potential roles in human neurogenesis and differentiation processes. A full and precise understanding of its specific biological functions remains under investigation, and to date, there is no recognized pharmacological targeting or therapeutic application for ZNF286B[2][1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 286B (ZNF286B).